title: Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
abstract: OBJECTIVE
  To report a retrospective series of choroidal neovascularization (CNV) patients treated with intravitreal ranibizumab with good baseline vision from causes other than age-related macular degeneration (AMD).
  
  
  METHODS
  We retrospectively reviewed 12 eyes of 12 patients with CNV secondary to non-AMD who received intravitreal ranibizumab injections. Patients with baseline best-corrected visual acuity (BCVA) above 20/63 were included in the study. All patients were followed up at least for 12 months. BCVA measurement, fundus examination, and OCT examination of the patients were performed at each visit. Optical coherence tomography (OCT), fundus photo, fundus autofluorescence, and fundus fluorescein angiography examination of the eyes were obtained. Primary outcome measures were the changing in BCVA and central foveal thickness (CFT). Any ocular or systemic side-effects were recorded.
  
  
  RESULTS
  The ages of patients ranged from 17 to 60. Twelve patients were diagnosed with non-AMD associated CNV: myopia (n = 3), central serous chorioretinopathy (n = 3), idiopathic (n = 2), multifocal choroiditis (n = 2), punctate inner choroidopathy (n = 1), and photo toxicity (n = 1). The improvement in visual acuity was statistically significant (p = 0.001). In the 12-month visit, all eyes had improvement in visual acuity except two eyes. The reduction of the mean CFT was statistically significant (p = 0.001). The CFT of all patients decreased in the 12-month visit. There was no significant difference in comparison of the mean intraocular pressure (p = 0.790). The group received a total of 52 intravitreal injections. The mean number of intravitreal injections was 4.3 (ranged from 3-8).
  
  
  CONCLUSIONS
  Ranibizumab seems to be an effective and safe treatment option for CNVs secondary to non-AMD causes in patients with relatively good baseline BCVAs.
authors.affiliation: Ophthalmology Department, Antalya Education and Research Hospital , Antalya , Turkey and.
authors.forename: Muhammet Kazim
authors.initials: MK
authors.lastname: Erol
authors.forename: Ozdemir
authors.initials: O
authors.lastname: Ozdemir
authors.forename: Deniz Turgut
authors.initials: DT
authors.lastname: Coban
authors.forename: Basak Bostanci
authors.initials: BB
authors.lastname: Ceran
authors.forename: Mehmet
authors.initials: M
authors.lastname: Bulut
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002833:Choroiditis / Q000150:complications; D005128:Eye Diseases / Q000150:complications; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab